257 related articles for article (PubMed ID: 36197958)
1. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
Monestime S; Al Sagheer T; Tadros M
Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
[TBL] [Abstract][Full Text] [Related]
3. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
5. Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
Combes FP; Li YF; Hoch M; Lorenzo S; Ho YY; Sy SKB
Clin Pharmacol Ther; 2022 Nov; 112(5):1040-1050. PubMed ID: 35776072
[TBL] [Abstract][Full Text] [Related]
6. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
Roskoski R
Pharmacol Res; 2022 Apr; 178():106156. PubMed ID: 35257901
[TBL] [Abstract][Full Text] [Related]
7. Asciminib in chronic myeloid leukemia.
Assanto GM; Scalzulli E; Breccia M
Drugs Today (Barc); 2022 Oct; 58(10):479-489. PubMed ID: 36305542
[TBL] [Abstract][Full Text] [Related]
8. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
Tesileanu CMS; Michaleas S; Gonzalo Ruiz R; Mariz S; Fabriek BO; van Hennik PB; Dedorath J; Dekic B; Unkrig C; Brandt A; Koenig J; Enzmann H; Delgado J; Pignatti F
Oncologist; 2023 Jul; 28(7):628-632. PubMed ID: 37141403
[TBL] [Abstract][Full Text] [Related]
9. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
[TBL] [Abstract][Full Text] [Related]
10. Asciminib for chronic myeloid leukaemia: Next questions.
Shanmuganathan N; Hughes TP
Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
[TBL] [Abstract][Full Text] [Related]
11. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
[TBL] [Abstract][Full Text] [Related]
12. Asciminib as a third line option in chronic myeloid leukemia.
Laganà A; Scalzulli E; Carmosino I; Martelli M; Breccia M
Int J Hematol; 2023 Jan; 117(1):16-23. PubMed ID: 35930119
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
14. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D; Hughes TP
Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
[TBL] [Abstract][Full Text] [Related]
15. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
Cortes JE; Hochhaus A; Takahashi N; Larson RA; Issa GC; Bombaci F; Ramscar N; Ifrah S; Hughes TP
Future Oncol; 2022 Dec; 18(38):4161-4170. PubMed ID: 36524980
[TBL] [Abstract][Full Text] [Related]
16. Asciminib: First Approval.
Deeks ED
Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
[TBL] [Abstract][Full Text] [Related]
18. [Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with
Lai HR; Wu QM; Yang YZ; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1579-1583. PubMed ID: 37846720
[No Abstract] [Full Text] [Related]
19. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
Yeung DT; Shanmuganathan N; Hughes TP
Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
[TBL] [Abstract][Full Text] [Related]
20. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Manley PW; Barys L; Cowan-Jacob SW
Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
